Article Text

other Versions

PDF
Systematic review with meta analysis
Aspirin reduces cardiovascular events in primary prevention of cardiovascular disease but at a near equivalent risk of increased bleeding
  1. Michael D Miedema1,
  2. Salim S Virani2
  1. 1Minneapolis Heart Institute, Minneapolis, Minnesota, USA
  2. 2Michael E. DeBakey Veterans Affairs Medical Center and Baylor College of Medicine, Houston, Texas, USA
  1. Correspondence to : Professor Salim S Virani, Health Services Research and Development (152), 2002 Holcombe Boulevard, Houston, TX 77030, USA; virani{at}bcm.edu

Statistics from Altmetric.com

Commentary on: OpenUrlCrossRefPubMed

Context

The use of aspirin in primary prevention of cardiovascular disease (CVD) remains controversial, as randomised controlled trials (RCTs) have produced mixed results. Recently, the United States Preventive Services Task Force (USPSTF) published updated recommendations on the use of aspirin for primary prevention of CVD and colorectal cancer.1 This systematic review and meta-analysis served as the basis for these USPSTF recommendations for primary CVD prevention.

Methods

All trials from the previous 2009 USPSTF guideline on the use of aspirin for primary CVD prevention (minimum of 75 mg every other day for 1 year or more) in adults aged 40 or more were included, and a comprehensive literature search for additional trials from January 2008 to …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.